Phase II trial of elliptinium in advanced renal cell carcinoma.

Forty patients with advanced renal cell carcinoma were treated with elliptinium by a weekly infusion of 100 mg/m2. Of 38 evaluable patients, five had an objective response (13.2%). Average response duration was 8 months (range, 5-11). The major dose-limiting toxic effect was induction of antielliptinium antibodies, with the risk of intravascular hemolysis. Elliptinium has modest activity in advanced renal cell cancer and does not produce myelosuppression.
AuthorsP Caillé, J M Mondesir, J P Droz, P Kerbrat, A Goodman, J P Ducret, C Theodore, M Spielman, J Rouëssé, J L Amiel
JournalCancer treatment reports (Cancer Treat Rep) 1985 Jul-Aug Vol. 69 Issue 7-8 Pg. 901-2 ISSN: 0361-5960 [Print] UNITED STATES
PMID4016798 (Publication Type: Journal Article)
Chemical References
  • Alkaloids
  • Antibodies
  • Antineoplastic Agents
  • Ellipticines
  • elliptinium
  • Adult
  • Aged
  • Alkaloids (therapeutic use)
  • Antibodies (analysis)
  • Antineoplastic Agents (adverse effects, immunology, therapeutic use)
  • Carcinoma, Renal Cell (drug therapy, secondary)
  • Drug Evaluation
  • Ellipticines (adverse effects, immunology, therapeutic use)
  • Female
  • Humans
  • Kidney Neoplasms (drug therapy)
  • Male
  • Middle Aged

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: